Longport CE-marks Episcan ultrasound system:
This article was originally published in Clinica
Executive Summary
Longport has CE-marked its Episcan ultrasound system for sale in Europe. The device images the skin and underlying soft tissue to a very high resolution enabling doctors to non-invasively assess and monitor a number of dermatological conditions, says the Swarthmore, Pennsylvania company. Longport plans to launch the product later this year.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.